Educate the Educators: Cervical Cancer Screening & the HPV Vaccine
July 26, 2018 • Denver, CO
The introduction of HPV vaccines in 2006 and the widespread adoption of HPV testing created a need for educating the clinical community about the role of HPV infections in anogenital disease, appropriate clinical usages of HPV testing, and about the potential benefits of vaccination against HPV infections. This program will address confusion in the clinical community after the introduction of cotesting, and the first generation of HPV vaccine—with the greatest challenge being in the smaller and mid-sized communities that lack clinicians who have expertise in this area.
Upon completion of this educational activity, participants should be able to:
- Describe important elements of the biology, epidemiology, and natural history of HPV infections and their relationship to the development of precancers and cancers of the lower genital tract including those of the cervix, vagina, vulva, anus and perianal areas;
- Identify the immune response to HPV infection, and the cost of HPV infections to the individual and society;
- Identify the content (genotypes) of available FDA licensed HPV vaccines, and understand important elements of vaccine immunogenicity and efficacy;
- Discuss recommendations for use of the HPV vaccine and the limitations of the effectiveness of HPV vaccines;
- Appropriately counsel patients, parents of patients and clinicians about the use of HPV vaccines;
- Discuss important elements of current US cervical cancer screening guidelines;
- Describe the different types of HPV testing methods currently available and their relative strengths and limitations;
- Discuss the accepted clinical uses of HPV assays in screening, triage and management of HPV-associated conditions for the general population, specific age groups, and populations with unusual risk profiles;
- Interpret consensus screening and management guidelines and the new interim guidance for primary HPV screening and how to apply them in a clinical setting; and,
- Apply HPV testing and relevant diagnostic tests to clinical practice in a directed, evidence-based and cost-effective manner.
Continuing Medical Education (CME)
ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credit(s)TM
ASCCP designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As an accredited provider of CME credit, ASCCP has implemented a process to ensure that anyone who is in a position to affect the content of an educational activity has disclosed all relevant financial relationships with any commercial interest. Any conflicts of interest have been resolved by ASCCP prior to the activity.
The following person(s) disclosed relevant financial relationships:
- P. Patricia Cason, MS, FNP-BC – Education Committee Chair, Faculty – Merck (Consultant, Advisory Board, Trainer, Speaker); Teva (Consultant, Advisory Board, Trainer, Speaker); ContraMed (Consultant, Advisory Board, Trainer); Medicines 360 (Trainer, Speaker); CooperSurgical (Consultant, Advisory Board).
The following person(s) disclosed no relevant financial relationships:
- Herschel Lawson, MD – Content Reviewer, Editor
- Rebecca Perkins, MD – Content Reviewer, Editor
- Colleen Stockdale, MD, MS – Content Reviewer, Editor
- Alan Waxman, MD, MPH – Faculty
- Amy Wiser, MD – Faculty
- Christina Arnold – Staff
- Kerry Curtis – Staff
- Cari Price – Staff
- Mary Stanley – Staff
- Alisha Yocum – Staff
This activity is supported by independent education grants from BD Diagnostics and Merck.